• 1
    Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 52635.
  • 2
    Van Hogezand RA, Eichhorn RF, Choudry A, Veenendaal RA, Lamers BHW. Malignancies in inflammatory bowel disease: Fact or fiction? Scand J Gastroenterol 2002; 235: (Suppl.) 4853.
  • 3
    Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990; 76: 65563.
  • 4
    Warren BF, Watkins PE. Animal models of inflammatory bowel disease. J Pathol 1994; 172: 3136.
  • 5
    Mori H, Ohbayashi F, Hirono I, Shimada T, Williams GM. Absence of genotoxicity of the carcinogenic sulfated polysaccharides carrageenan and dextran sulfate in mammalian DNA repair and bacterial mutagenicity assays. Nutr Cancer 1984; 6: 927.
  • 6
    Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. Novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990; 98: 694702.
  • 7
    Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J, Ohkusa T. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 2002; 17: 107883.
  • 8
    Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003; 94: 96573.
  • 9
    Rogers AE, Nauss KM. Rodent models for carcinoma of the colon. Dig Dis Sci 1985; 30: 87S102S.
  • 10
    Pozharisski KM, Likhachev AJ, Klimashevski VF, Shaposhnikov JD. Experimental intestinal cancer research with special reference to human pathology. Adv Cancer Res 1979; 30: 165237.
  • 11
    Ross JS. Experimental large intestinal adenocarcinoma induced by hydrazines and human colorectal cancer: a comparative study. In: MaltRA, WilliamsonRCN, eds. Colonic Carcinogenesis. MTP Press, Hingham, 1982; 187207.
  • 12
    Miller JR, Moon RT. Signal transduction through β-catenin and specification of cell fate during embryogenesis. Genes Dev 1996; 10: 252739.
  • 13
    Kishida S, Yamamoto H, Ikeda S, Kishida M, Sakamoto I, Koyama S, Kikuchi A. Axin, a negative regulator of the wnt signaling pathway, directly interacts with adenomatous polyposis coli and regulates the stabilization of β-catenin. J Biol Chem 1998; 273: 108236.
  • 14
    Dashwood RH, Suzui M, Nakagama H, Sugimura T, Nagao M. High frequency of β-catenin (Ctnnb1) mutations in the colon tumors induced by two heterocyclic amines in the F344 rat. Cancer Res 1998; 58: 11279.
  • 15
    Takahashi M, Fukuda K, Sugimura T, Wakabayashi K. β-Catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors. Cancer Res 1998; 58: 426.
  • 16
    Takahashi M, Nakatsugi S, Sugimura T, Wakabayashi K. Frequent mutations of the β-catenin gene in mouse colon tumors induced by azoxymethane. Carcinogenesis 2000; 21: 111720.
  • 17
    Koesters R, Hans MA, Benner A, Prosst R, Boehm J, Gahlen J, Doeberitz MK. Predominant mutation of codon 41 of the β-catenin proto-oncogene in rat colon tumors induced by 1,2-dimethylhydrazine using a complete carcinogenic protocol. Carcinogenesis 2001; 22: 188590.
  • 18
    Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 1997; 275: 178790.
  • 19
    Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, Aoki T, Miki Y, Mori T, Nakamura Y. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992; 1: 22933.
  • 20
    Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature 1992; 359: 2357.
  • 21
    Sparks AB, Morin PJ, Vogelstein B, Kinzler KW. Mutational analysis of the APC/β-catenin/Tcf pathway in colorectal cancer. Cancer Res 1998; 58: 11304.
  • 22
    Iwamoto M, Ahnen DJ, Franklin WA, Maltzman TH. Expression of β-catenin and full-length APC protein in normal and neoplastic colonic tissues. Carcinogenesis 2000; 21: 193540.
  • 23
    Cooper HS, Murthy S, Kido K, Yoshitake H, Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model. Relevance to colitis-associated neoplasia in the human. a study of histopathology, β-catenin and p53 expression and the role of inflammation. Carcinogenesis 2000; 21: 75768.
  • 24
    Hill KA, Wang KL, Stryker SJ, Gupta R, Weinrach DM, Rao MS. Comparative analysis of cell adhesion molecules, cell cycle regulatory proteins, mismatch repair genes, cyclooxygenase-2, and DPC4 in carcinomas arising in inflammatory bowel disease and sporadic colon cancer. Oncol Report 2004; 11: 9516.
  • 25
    Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory Invest 1993; 69: 23849.
  • 26
    Riddell RH, Goldman H, Ransohof DF, Appleman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC, Sommers SC, Yardley JH. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical application. Human Pathol 1983; 14: 93168.
  • 27
    Pascal RR. Dysplasia and early carcinoma in inflammatory bowel disease and colorectal carcinomas. Human Pathol 1994; 25: 116071.
  • 28
    Ward JM. Morphogenesis of chemically induced neoplasms of the colon and small intestine in rats. Laboratory Invest 1974; 30: 50513.
  • 29
    Bullions LC, Levine AJ. The role of β-catenin in cell adhesion, signal transduction, and cancer. Curr Opin Oncol 1998; 10: 817.
  • 30
    Morin PJ. β-Catenin signaling and cancer. Bioessays 1999; 21: 102130.
  • 31
    Brabletz T, Jung A, Kirchner T. β-Catenin and the morphogenesis of colorectal cancer. Virchows Arch 2002; 441: 111.
  • 32
    Hao XP, Pretlow TG, Rao JS, Pretlow TP. β-Catenin expression is altered in human colonic aberrant crypt foci. Cancer Res 2001; 61: 80858.
  • 33
    Walsh SV, Loda M, Torres CM, Antonioli D, Odze R. P53 and β-catenin expression in chronic ulcerative colitis − associated polypoid dysplasia and sporadic adenomas: an immunohistochemical study. Am J Surg Pathol 1999; 23: 9639.
  • 34
    Mikami T, Mitomi H, Hara A, Yanagisawa N, Yoshida T, Tsuruta O, Okayasu I. Decreased expression of CD44, α-catenin, and deleted colon carcinoma and altered expression of β-catenin in ulcerative colitis-associated dysplasia and carcinoma, as compared with sporadic colon neoplasms. Cancer 2000; 89: 73340.
  • 35
    Aust DE, Terdiman JP, Willenbucher RF, Chew K, Ferrell L, Florendo C, Molinaro-Clark A, Baretton GB, Lohrs U, Waldman FM. Altered distribution of β-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers. Mod Pathol 2001; 14: 2939.
  • 36
    Erdman SH, Wu HD, Hixson LJ, Ahnen DJ, Gerner EW. Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats. Mol Carcinog 1997; 19: 13744.
  • 37
    Tanaka T, Suzuki R, Kohno H, Sugie S, Takahashi M, Wakabayashi K. Colonic adenocarcinomas rapidly induced by the combined treatment with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and dextran sodium sulfate in male ICR mice possess β-catenin gene mutations and increase immunoreactivity for β-catenin, cyclooxygenase-2, and inducible nitric oxide synthase. Carcinogenesis 2005; 26: 22938.
  • 38
    Takahashi M, Mutoh M, Kawamori T, Sugimura T, Wakabayashi K. Altered expression of β-catenin, inducible nitric oxide synthase and cyclooxygenase-2 in azoxymethane-induced rat colon carcinogenesis. Carcinogenesis 2000; 21: 131927.
  • 39
    Chiang JM, Chou YH, Chen TC, Ng KF, Lin JL. Nuclear β-catenin expression is closely related to ulcerative growth of colorectal carcinoma. Br J Cancer 2002; 86: 11249.
  • 40
    Tetsu O, McCormick F. β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999; 398: 4226.
  • 41
    He TC, Sparks AB, Rago C, Hermeking H, Zawel L, Da Costa LT, Morin PJ, Vogelstein B, Kinzler KW. Identification of c-MYC as a target of the APC pathway. Science 1998; 281: 150912.
  • 42
    Sakamoto C. Roles of COX-1 and COX-2 in gastrointestinal pathophysiology. J Gastroenterol 1998; 33: 61824.
  • 43
    Kankuri E, Asmawi MZ, Korpela R, Vapaatalo H, Moilanen E. Induction of iNOS in a rat model of acute colitis. Inflammation 1999; 23: 14152.
  • 44
    Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG, Billiar TR, Harris CC. Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res 1998; 58: 33441.
  • 45
    Takahashi M, Fukuda K, Ohata T, Sugimura T, Wakabayashi K. Increased expression of inducible and endothelial constitutive nitric oxide synthases in rat colon tumors induced by azoxymethane. Cancer Res 1997; 57: 12337.
  • 46
    Takahashi M, Wakabayashi K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci 2004; 95: 47580.
  • 47
    Araki Y, Okamura S, Hussain SP, Nagashima M, He P, Shiseki M, Miura K, Harris CC. Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res 2003; 63: 72834.
  • 48
    Mei JM, Hord NG, Winterstein DF, Donald SP, Phang JM. Expression of prostaglandin endoperoxide H synthase-2 induced by nitric oxide in conditionally immortalized murine colonic epithelial cells. FASEB J 2000; 14: 1188201.
  • 49
    Howe LR, Crawford HC, Subbaramaiah K, Hassell JA, Dannenberg AJ, Brown AM. PEA3 is up-regulated in response to Wnt1 and activates the expression of cyclooxygenase-2. J Biol Chem 2001; 276: 2010815.
  • 50
    Liu Y, Borchert GL, Phang JM. Polyoma enhancer activator 3, an Ets transcription factor, mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells. J Biol Chem 2004; 279: 18694700.
  • 51
    Suzuki R, Kohno H, Sugie S, Tanaka T. Sequential observations on the occurrence of preneoplastic and neoplastic lesions in the mouse colon treated with azoxymethane and dextrane sodium sulfate. Cancer Sci 2004; 95: 7217.